News | March 14, 2013

FDA Approves Jubilant HollisterStier as New Manufacturer for Definity Ultrasound Contrast Agent

March 14, 2013 — Lantheus Medical Imaging Inc. announced the U.S. Food and Drug Administration (FDA) has granted approval of a supplemental new drug application (sNDA) that allows Jubilant HollisterStier (JHS) to be a new manufacturing site for its ultrasound imaging agent, Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension.

Definity is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

“FDA approval of JHS as a new manufacturer for Definity is a major step forward in providing consistent and reliable supply to our customers,” said Jeff Bailey, Lantheus president and CEO. “Supply chain diversification is a significant priority for the company as we work to ensure long-term product availability to meet market demand. We remain dedicated to providing the highest quality products to our customers and the patients they serve.”

Definity is currently manufactured by Ben Venue Laboratories (BVL) in Bedford, Ohio. In August 2011, BVL announced it would exit the contract manufacturing services business over the next several years. In February 2012, Lantheus entered into a manufacturing and supply agreement with JHS for the manufacture of Definity. Additionally, the company entered into similar agreements with JHS in May 2012 for the manufacture and supply of Cardiolite and Neurolite, which are also currently manufactured by BVL. JHS will become Lantheus’s lead supplier of Definity, as well as Cardiolite and Neurolite, as BVL transitions out of the contract manufacturing services business. Lantheus is currently working to secure additional alternative suppliers for its key products as part of its ongoing supply chain diversification strategy.

For more information: www.definityimaging.com

Related Content

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
Siemens Healthineers Receives FDA Clearance for TrueFusion Structural Heart Disease Feature
Technology | Cardiovascular Ultrasound| September 06, 2017
The U.S. Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens...
GE’s blood speckle imaging (BSI) software shows the flow of blood cells’ trajectories. It is a form of blood vector flow imaging.

GE’s blood speckle imaging (BSI) software offers the ability to view a graphical representation of the blood cells’ trajectories.

News | Cardiovascular Ultrasound| September 01, 2017
Cardiologists are constantly on the lookout for new methods to examine the heart using new imaging technology advance
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| August 30, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init